FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, in particular to an antibody, which specifically binds to latent myostatin, as well as to its production method. Nucleic acid encoding the above-mentioned antibody, as well as a cell containing it are also disclosed.
EFFECT: invention is effective for specific binding to myostatin.
7 cl, 31 dwg, 30 tbl, 34 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES TO MYOSTATIN AND THEIR APPLICATION METHODS | 2017 |
|
RU2778945C2 |
| ANTIBODIES TO MYOSTATIN, POLYPEPTIDES CONTAINING FC REGION VARIANTS AND METHODS OF THEIR USE | 2015 |
|
RU2799522C2 |
| ANTIBODIES TO DENGUE VIRUS, POLYPEPTIDES CONTAINING FC-REGION OPTIONS AND THEIR APPLICATION METHODS | 2017 |
|
RU2758596C2 |
| IL-12 HETERODIMERIC FC FUSION PROTEINS | 2019 |
|
RU2819097C2 |
| ANTI-PVRIG ANTIBODIES AND METHODS OF USING | 2016 |
|
RU2732042C2 |
| BISPECIFIC 2+1 ANTIBODIES | 2018 |
|
RU2797305C2 |
| BISPECIFIC ANTIBODIES SPECIFIC RELATIVELY TO COSTIMULATORY TNF-RECEPTOR | 2016 |
|
RU2761115C1 |
| HYBRID PROTEINS OF sPD-1-Fc VARIANT | 2019 |
|
RU2785993C2 |
| LIGAND-BINDING MOLECULE WITH REGULATED LIGAND-BINDING ACTIVITY | 2017 |
|
RU2803067C2 |
| BISPECIFIC ANTIBODIES BINDING TO TFR | 2019 |
|
RU2810756C2 |
